BC Week In Review | Apr 27, 2015
Clinical News

DFN-11 regulatory update

Dr. Reddy’s submitted an NDA to FDA for DFN-11 to treat acute migraine episodes in patients for whom other treatment has failed. DFN-11 is an undisclosed drug-device combination. The NDA was submitted under section 505(b)(2)...
Items per page:
1 - 1 of 1